Gene expression of 61 FFPE tissues of DLBCL patients at high-risk (aaIPI 2 or 3)

Current staging classifications do not accurately predict the benefit of high-dose chemotherapy (HDC) with autologous stem-cell transplantation (ASCT) for patients with diffuse large B-cell lymphoma (DLBCL) at high risk (age-adjusted International Index [aaIPI] score 2 or 3), who have achieved first complete remission after R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) treatment. We aim to construct a genetic prognostic model for improving individualized risk stratification and response prediction for HDC/ASCT therapy. We identified differentially expressed mRNAs associated with relapse of DLBCL. Affymetrix Human U133 Plus 2.0 microarrays (ThermoFisher Scientific, Waltham, MA, USA) identified differentially expressed mRNAs between 34 relapse and 27 relapse-free DLBCL patients.